Please be advised that in light of the UK Prime Minister’s announcement of a new national lockdown commencing from 5th January 2021 and in accordance with Government guidance, IXICO’s Annual General Meeting (AGM) will now be held virtually on Thursday 21 January 2021. The extension of the Corporate Insolvency and Governance Act 2020 provides temporary provisions for companies to use alternative methods to fulfil statutory requirements, of which we have decided to take advantage. All other aspects of the AGM will remain as set out in the Notice of Annual General Meeting dated 18th December 2020.
IXICO has extensive experience in supporting regulatory-compliant clinical research, working with clients on the selection and use of neuroimaging and digital biomarkers - whether directly with your teams or as part of collaborative consortia.Read more
We have extensive experience in definition and delivery of early phase clinical development, where rigorous patient safety runs hand-in-hand with flexibility around trial design and data analytics.
IXICO's global network of over 2,000 imaging sites across 75 countries and custom TrialTracker platform ensure that large-scale trials can be set up quickly and efficiently to deliver data that is as reliable as it is regulatory compliant.Read more
IXICO understands the challenges of extended longitudinal studies, and the importance of monitoring patient safety and drug utilization for ongoing optimization of patient pathways post marketing.Read more
IXICO has supported important Alzheimer's Disease research since 2007 and continues to assist many pharmaceutical companies in their search for novel therapies. We have provided both MRI and PET imaging biomarkers for over 70 clinical studies in neuroscience, of which, over 30 have been in Alzheimer's disease.Read more
IXICO is the leading company for Huntington's disease (HD) specialist imaging. Our neuroscience expertise enables global, regulatory compliant imaging and digital biomarker analytical services for clinical development. We are a trusted imaging provider and preferred supplier for pharma and biotech, with IXICO providing advanced imaging analytics for 11 HD trials.Read more
IXICO first supported a clinical study for PD in 2016 and continue to invest in our technological solutions to support clinical trials in this area. PD is the second most common neurodegenerative disease, after Alzheimer’s disease. An estimated 7 to 10 million people worldwide are living with PD.Read more
We have been involved in MS since 2015 through our Assessa PML collaboration with big pharma. Multiple Sclerosis is a condition that affects the brain and spinal cord. It is the most common autoimmune disorder of the central nervous system, affecting around 2.3 million people globally as of 2015.Read more
Progressive Supranuclear Palsy (PSP) is a Parkinsonian neurological rare condition caused by the premature loss of nerve cells in certain parts of the brain, which leads to difficulties with balance, movement, vision, speech and swallowing. IXICO has supported clinical trials in this area since 2015, providing advanced analytics for 5 clinical trials across 230 global sites.Read more
IXICO specialises in data collection, optimisation, and analytics of rare neurological disorders, including but not limited to Huntington's Disease (HD), Progressive Supranuclear Palsy (PSP), Multiple System Atrophy (MSA), and Spinocerebellar Ataxia (SCA).Read more
IXICO is developing and validating new machine learning algorithms to analyse wearable biosensor data for specific neurodegenerative diseases. These disease-specific algorithms can improve the sensitivity and specificity of standard algorithms to measure physiological parameters such as sleep, activity and circadian rhythm.
IXICO's compliant image and digital data management, provides all you need to manage the complex data workflows that come with many clinical trials. IXICO also offers a secure online digital platform as an enabler of clinical decision support for patient selection and post-marketing surveillance.